After protracted legal battling, GSK has agreed to pay up to $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

Corrects headline to say 'settlements' instead of 'settlement' British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker's settlement with ...

(Bloomberg) -- GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer. "GSK today ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...